Latest revenue
$1.7M
as of 2026-03-31
Latest net income
$-93.1M
as of 2026-03-31
Net margin
-5344.8%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ALMS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $52.3M
- Enterprise value
- $-11.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.09×
- Dividend yield
- 0.0%
- 52-wk high
- $30.60
- 52-wk low
- $2.76
- Beta
- —
- Shares out
- 2.7M
5-year trend
What this company does
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations and the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q in conjunction with the financial statements and related notes thereto as of and for the year ended December 31, 2025 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 19, 2026. This…
AI summary unavailable — showing raw filing excerpt
Generated from ALMS's filing dated 2026-05-14
Key risks
Item 1A. Risk Factors Risk Factors Investing in our common stock involves a high degree of risk. Before deciding to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this Quarterly Report on Form 10-Q. We cannot assure you that any of the events discussed below will not occur. These events could adversely impact our business, financial…
AI summary unavailable — showing raw filing excerpt
Generated from ALMS's filing dated 2026-05-14
Profitability
Operating margin
-1886.9%
Net margin
-1011.7%
Return on equity
-80.8%
28.6%Return on assets
-59.1%
31.5%Leverage
Debt / equity
0.37×
18.1%Debt / assets
26.9%
13.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.7M | -90.0% | $-93.1M | +6.0% | -5344.8% |
Q4 2025 2025-12-31 | $1.9M | — | $6.0M | +106.4% | 312.7% |
Q3 2025 2025-09-30 | $2.1M | — | $-110.8M | -18.9% | -5360.7% |
Q2 2025 2025-06-30 | $2.7M | — | $-39.6M | +29.8% | -1486.9% |
Q1 2025 2025-03-31 | $17.4M | — | $-99.0M | -98.5% | -569.1% |
Q4 2024 2024-12-31 | — | — | $-94.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-93.1M | -114.7% | — |
Q2 2024 2024-06-30 | — | — | $-56.5M | -55.7% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALMS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$51.0M
Insider selling
$0
Net activity
+$51.0M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALMS
Institutional value
$515.9M
Total shares held
23.5M
Distinct holders
88
-45 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.2M | $158.0M | +2.6M (+57.0%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0M | $88.8M | — | New |
| 3 | UBS Group AG | 3.1M | $67.3M | +2.9M (+2579.8%) | Added |
| 4 | Invesco Ltd. | 1.5M | $33.3M | +1.1M (+258.3%) | Added |
| 5 | PRINCIPAL FINANCIAL GROUP INC | 1.1M | $23.3M | — | New |
| 6 | JPMORGAN CHASE & CO | 861.6K | $17.4M | +505.2K (+141.8%) | Added |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 712.6K | $15.7M | — | New |
| 8 | PRUDENTIAL FINANCIAL INC | 538.7K | $11.9M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 527.3K | $11.6M | — | New |
| 10 | ROYCE & ASSOCIATES LP | 476.4K | $10.5M | — | New |
| 11 | Nuveen, LLC | 319.2K | $7.0M | +149.7K (+88.3%) | Added |
| 12 | TOWERVIEW LLC | 222.3K | $4.9M | -272.7K (-55.1%) | Trimmed |
| 13 | STIFEL FINANCIAL CORP | 209.7K | $4.6M | +0 (+0.0%) | No change |
| 14 | Bank of New York Mellon Corp | 206.7K | $4.6M | +46.6K (+29.1%) | Added |
| 15 | Hudson Bay Capital Management LP | 193.4K | $4.3M | — | New |
| 16 | Trium Capital LLP | 191.4K | $4.2M | -701.7K (-78.6%) | Trimmed |
| 17 | TD ASSET MANAGEMENT INC | 191.2K | $4.2M | — | New |
| 18 | ACT CAPITAL MANAGEMENT, LLC | 174.3K | $3.8M | — | New |
| 19 | Ensign Peak Advisors, Inc | 169.5K | $3.7M | — | New |
| 20 | Russell Investments Group, Ltd. | 162.2K | $3.6M | +147.2K (+979.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALMS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.